| Literature DB >> 24512292 |
Barton Phillips1, Ruby Cai, William Delaney, Zhimin Du, Mingzhe Ji, Haolun Jin, Johnny Lee, Jiayao Li, Anita Niedziela-Majka, Michael Mish, Hyung-Jung Pyun, Joe Saugier, Neeraj Tirunagari, Jianhong Wang, Huiling Yang, Qiaoyin Wu, Chris Sheng, Catalin Zonte.
Abstract
The exploration of novel inhibitors of the HCV NS4B protein that are based on a 2-oxadiazoloquinoline scaffold is described. Optimization to incorporate activity across genotypes led to a potent new series with broad activity, of which inhibitor 1 displayed the following EC50 values: 1a, 0.08 nM; 1b, 0.10 nM; 2a, 3 nM; 2b, 0.6 nM, 3a, 3.7 nM; 4a, 0.9 nM; 6a, 3.1 nM.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24512292 DOI: 10.1021/jm401646w
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446